Mesoblast Limited vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.54 (market cap $28.69M). The key difference: Mesoblast Limited is far larger — about 61× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 60 Days on average.
| MESO | QDTY | |
|---|---|---|
Market Cap | $1.75B | $28.69M |
Volume | 239,027 | 22,490 |
Sector | Health | Income / Options Overlay |
52-Week High | $20.96 | $46.71 |
52-Week Low | $13.19 | $36.57 |
Typical Hold Time | 14 Days | 60 Days |
Enterprise Value | $1.83B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →